LONDON – Adaptimmune Ltd. released positive data from the ongoing open-label Phase I/II trial of its autologous T-cell immunotherapy in treating multiple myeloma, reporting a 77 percent complete response rate in the 20 patients treated to date, at 100 days post-infusion of the modified cells.